Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04999995 · ClinicalTrials.gov registry record
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 17
- Enrollment target
NCT04999995: Completed study, sponsored by VA Office of Research and Development.
NCT04999995 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04999995 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
Autophagy is considered an important component of Heart failure progression. Deubiquitination enzymes play an important role in autophagy. An important regulatory process within the autophagy pathway is ubiquitination. Ubiquitination targets proteins for degradation. On the contrary, de-ubiquitinating proteins (such as UCHL1) reverses this process. Studies have demonstrated deubiquitination to be linked to certain pathological processes, such as heart failure. UCHL1 will be examined as a potential marker of disease progression in acute decompensated heart failure.
Primary Outcome
Assess accuracy of UCHL1 to diagnose ADHF as well as correlate with improvement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2025-03-17 |
What the finished NCT04999995 record still lists
NCT04999995 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04999995 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04999995 about?
NCT04999995 is a clinical study titled "Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure". Autophagy is considered an important component of Heart failure progression. Deubiquitination enzymes play an important role in autophagy. An important regulatory process within the autophagy pathway is ubiquitination. Ubiquitination targets proteins for degradation. On the contrary, de-ubiquitinati...
What is the current status of trial NCT04999995?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2021-06-01. Estimated completion is 2025-03-17.
Who is sponsoring clinical trial NCT04999995?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI